IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk

News   Sep 05, 2016

 
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
 
 
 
 

RELATED ARTICLES

Biofortuna Raises £1.6 Million in Funding Round

News

Biofortuna Ltd has raised £1.6 million, allowing the company to take its blood group genotyping assays into clinical trails and commercialisation.

READ MORE

Cambridge Epigenetix, NuGEN Technologies Sign Agreement to Combine Leading Technologies in Epigenetics Research

News

Cambridge Epigenetix and NuGEN Technologies come together to integrate the oxidative bisulfite sequencing (oxBS-Seq) with NGS library preparation kits.

READ MORE

Major Cause of Drug-resistance in Prostate Cancer Patients Identified

News

A recent Nature Medicine paper outlines the role of mutations within the SPOP gene on the development of resistance to one class of drugs.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE